Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy

doi:10.3969/j.issn.1673-8640.2022.05.004

Abstract

Abstract: Objective To investigate the predictive value of serum miR-21 and miR-135a expression in the recurrence and metastasis of gastric cancer patients after chemotherapy. Methods A total of 100 gastric cancer patients（gastric cancer group） who underwent chemotherapy were enrolled,and 50 healthy subjects were enrolled as control group. The clinical data of all the patients were collected. Follow-up started 1 month after chemotherapy,and the follow-up time was 24 months. The relative expression levels of serum miR-21 and miR-135a in control subjects and gastric cancer patients before chemotherapy and at 3,8,13,18,and 24 months after chemotherapy were determined. Receiver operating characteristic（ROC） curve was used to evaluate the efficiency of miR-21 and miR-135a in judging the prognosis of gastric cancer. Results Compared with control group,the relative expression of miR-21 in gastric cancer group before chemotherapy increased（P<0.05）,and the relative expression of miR-135a decreased（P<0.05）. The relative expression levels of serum miR-21 and miR-135a before chemotherapy were related to lymph node metastasis,differentiation degree and the depth of invasion in patients with gastric cancer（P<0.05）,but they were not related to age,sex,TNM stage and the presence or absence of distant metastasis（P>0.05）. The 3 cases of 100 gastric cancer patients were lost to follow-up,and 66 cases（68%） had recurrence or metastasis. The relative expression of serum miR-21 in patients with recurrence or metastasis after chemotherapy increased with the extension of follow-up time（P<0.05）,and the relative expression of serum miR-135a decreased with the extension of follow-up time（P<0.05）. ROC curve analysis results showed that the areas under curves（AUC） of miR-21 and miR-135a single determinations to judge the poor prognosis of gastric cancer were 0.789 and 0.826,respectively. Taking both positive results as combined determination positive,and taking both negative results as combined determination negative,the sensitivity and specificity of the combined determination of miR-21 and miR-135a in judging the prognosis of gastric cancer were 91.2% and 67.8%,respectively. Conclusions The expressions of miR-21 and miR-135a in serum of patients with gastric cancer are abnormal,and the expression level is closely related to lymph node metastasis,the degree of differentiation and the depth of invasion. The combined determination of serum miR-21 and miR-135a has a value in judging the recurrence or metastasis of gastric cancer after chemotherapy.

Key words: MiR-21, MiR-135a, Gastric cancer, Chemotherapy, Recurrence, Metastasis

LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy[J]. Laboratory Medicine, 2022, 37(5): 417-422.

Figures/Tables 7

References 21

[1]	YANG L, ZHENG R, WANG N, et al. Incidence and mortality of stomach cancer in China,2014[J]. Chin J Cancer Res, 2018, 30(3):291-298. DOI URL
[2]	TOYA Y, NAKAMURA S, URUSHIKUBO J, et al. Diffuse cystic malformation with early gastric cancer[J]. J Gastrointest Surg, 2018, 22(6):1130-1131. DOI URL
[3]	ZUO X, LI B, ZHU C, et al. Stoichiogenomics reveal oxygen usage bias,key proteins and pathways associated with stomach cancer[J]. Sci Rep, 2019, 9(1):11344. DOI URL
[4]	MITRA R, SUN J, ZHAO Z. MicroRNA regulation in cancer:one arm or two arms?[J]. Int J Cancer, 2015, 137(6):1516-1518. DOI URL
[5]	HAO N B, HE Y F, LI X Q, et al. The role of miRNA and lncRNA in gastric cancer[J]. Oncotarget, 2017, 8(46):81572-81582. DOI URL
[6]	KOENIG A B, BARAJAS J M, GUERRERO M J, et al. A comprehensive analysis of argonaute-clip data identifies novel,conserved and species-specific targets of mir-21 in human liver and hepatocellular carcinoma[J]. Int J Mol Sci, 2018, 19(3):851. DOI URL
[7]	UOZAKI H, MORITA S, KUMAGAI A, et al. Stromal miR-21 is more important than miR-21 of tumour cells for the progression of gastric cancer[J]. Histopathology, 2014, 65(6):775-783. DOI URL
[8]	WANG H, TAN Z, HU H, et al. MicroRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1[J]. BMC Cancer, 2019, 19(1):738. DOI URL
[9]	WU H, HUANG M, CAO P, et al. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation[J]. Cancer Biol Ther, 2012, 13(5):281-288. DOI URL
[10]	WANG Q, ZHANG H, SHEN X, et al. Serum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer[J]. Ann Clin Biochem, 2017, 54(1):76-85. DOI URL
[11]	ZHANG X, GAO F, ZHOU L, et al. UCA1 regulates the growth and metastasis of pancreatic cancer by sponging mir-135a[J]. Oncol Res, 2017, 25(9):1529-1541. DOI URL
[12]	陕飞, 李子禹, 张连海, 等. 国际抗癌联盟及美国肿瘤联合会胃癌TNM分期系统(第8版)简介及解读[J]. 中国实用外科杂志, 2017, 37(1):15-17.
[13]	ALEEBRAHIM-DEHKORDY E, NASRI H, BARADARAN A, et al. Medicinal plants,effective plant compounds(compositions) and their effects on stomach cancer[J]. Int J Prev Med, 2017, 8:96.
[14]	YI D, WANG R, SHI X, et al. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p expression[J]. Oncol Rep, 2020, 43(5):1375-1386.
[15]	ZHANG X, NIE Y, LI X, et al. MicroRNA-181a functions as an oncomir in gastric cancer by targeting the tumour suppressor gene ATM[J]. Pathol Oncol Res, 2014, 20(2):381-389. DOI URL
[16]	ZENG J F, MA X Q, WANG L P, et al. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer[J]. World J Gastroenterol, 2017, 23(13):2337-2345. DOI URL
[17]	CHAN S H, WU C W, LI A F, et al. MiR-21 microRNA expression in human gastric carcinomas and its clinical association[J]. Anticancer Res, 2008, 28(2A):907-911.
[18]	BAO L, YAN Y, XU C, et al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways[J]. Cancer Lett, 2013, 337(2):226-236. DOI URL
[19]	MOTOYAMA K, INOUE H, MIMORI K, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer[J]. Int J Oncol, 2010, 36(5):1089-1095.
[20]	ZHANG C, CHEN X, CHEN X, et al. MiR-135a acts as a tumor suppressor in gastric cancer in part by targeting KIFC1[J]. Onco Targets Ther, 2016, 9:3555-3563.
[21]	ZHANG Z, REN L, ZHAO Q, et al. TRPC1 exacerbate metastasis in gastric cancer via ciRS-7/miR-135a-5p/TRPC1 axis[J]. Biochem Biophys Res Commun, 2020, 529(1):85-90. DOI URL

项目	正向引物（5'~3'）	反向引物（5'~3'）	长度/bp
miR-21	CTTTGTATCGTTAATTGT	TGTCGTAATAAGCTAGTCTT	22
miR-135a	TGTAGTCCATTAATCGGT	GTAGTCATTAGTCAATTACT	22
U6	CGTTAGTCAATCAATCAA	GTCATTAAGTTCATTTAATT	94

项目	正向引物（5'~3'）	反向引物（5'~3'）	长度/bp
miR-21	CTTTGTATCGTTAATTGT	TGTCGTAATAAGCTAGTCTT	22
miR-135a	TGTAGTCCATTAATCGGT	GTAGTCATTAGTCAATTACT	22
U6	CGTTAGTCAATCAATCAA	GTCATTAAGTTCATTTAATT	94

组别	例数	miR-21	miR-135a
正常对照组	50	0.76±0.21	1.33±0.32
胃癌组	100	2.32±0.11	0.21±0.09
t值		16.322	14.567
P值		0.000	0.000

组别	例数	miR-21	miR-135a
正常对照组	50	0.76±0.21	1.33±0.32
胃癌组	100	2.32±0.11	0.21±0.09
t值		16.322	14.567
P值		0.000	0.000

临床病理特征	例数	miR-21	miR-135	临床病理特征	例数	miR-21	miR-135
年龄				浸润深度
<60岁	45	2.33±0.27	0.24±0.01	黏膜下各层	41	1.92±0.21	0.33±0.15
≥60岁	55	2.22±0.41	0.19±0.07	浆膜层	59	2.60±0.36	0.11±0.01
t值		0.623	0.752	t值		1.452	0.941
P值		0.694	0.598	P值		0.008	0.008
性别				远处转移
男	62	2.12±0.37	0.23±0.09	有	39	2.38±0.16	0.18±0.13
女	38	2.36±0.41	0.20±0.08	无	61	2.27±0.32	0.25±0.09
t值		0.701	0.964	t值		1.642	1.045
P值		0.814	0.701	P值		0.865	0.089
淋巴结转移				TNM分期
有	40	2.88±0.56	0.28±0.11	Ⅰ~Ⅱ期	31	2.42±0.16	0.22±0.01
无	60	1.74±0.31	0.16±0.07	Ⅲ~Ⅳ期	69	2.24±0.17	0.22±0.009
t值		2.311	1.034	t值		1.231	0.945
P值		0.021	0.009	P值		0.587	0.102
分化程度
低分化	49	1.81±0.26	0.32±0.13
中高分化	51	2.61±0.19	0.15±0.06
t值		3.021	0.455
P值		0.012	0.010